KFDA approves Retisert for treatment of affecting posterior segment of eye

The Korea Food and Drug Administration says it has approved Bausch & Lomb's Retisert (fluocinolone acetonide) 0.59 mg, the world's first intravitreal drug implant for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Uveitis is one of the leading causes of blindness for middle-aged people in the Western world. It is estimated to cause 10% to 15% of a...